26
nanotimes
Companies Facts
volume weighted average share price. Austock Secu- rities Limited was the lead manager of the transaction and was assisted in the USA by Chardan Capital Mar- kets LLC. These shares have been largely subscribed for by existing shareholders under the Company’s ASX Listing Rule 7.1 capacity. Also, as set out in the Company’s Appendix 4C released on April 29, Dyesol intends to offer a Share Purchase Plan (SPP) to all shareholders as of the record date on the same price and volume terms as the above placement. The terms and conditions of the SPP offer will be sent to all eligible shareholders shortly.
Separately, Dyesol has entered an agreement with Springtree Special Opportunities Fund, LP (Spring- Tree) under which SpringTree can invest between A$15.2 million and A$22.4 million in Dyesol over the next three years in monthly instalments (the Agreement). The Agreement is structured to provi- de funding flexibility, minimise dilution to existing shareholders while relating to the share price at the time of each monthly investment. Dyesol has the ability to terminate the Agreement at any time, at no cost if the price is below a specified level or after 12 months, or otherwise at a small break fee.
http://www.dyesol.com
E Ink®
Corporation and Chilin Technology Corpo- ration, a leading manufacturer of vertically inte-
grated flat panel displays, announced a partnership to bring low-power industrial and other specialized electrophoretic displays to the marketplace. The partnership makes the patented E Ink Vizplex™ imaging film available to Chilin for mass production, distribution and sales to consumers.
http://www.eink.com
F
EI (NASDAQ: FEIC) has shipped the 250th Helios NanoLab™ DualBeam™ system. Since its intro-
duction in 2006, the award-winning Helios NanoLab has experienced widespread market acceptance.
“The Helios NanoLab DualBeam provides the SEM and FIB performance needed to solve some of the critical roadblocks to advancing technology and sciences across many disciplines,” said John Wil- liams, vice president of marketing, FEI. “It has been adopted by leading semiconductor manufacturers for their most advanced research and development needs; it is being used by major academic and in- dustrial research laboratories for advanced material characterization and modification down to the single nanometer scale; and it has even expanded into the life sciences and oil & gas industries due to its ability to provide three-dimensional imaging at the nanosca- le.”
http://www.fei.com F
lamel Technologies (NASDAQ: FLML) has entered into a license agreement with a leading specialty
pharmaceutical company for development and com- mercialization of two molecules for pain indications. Pursuant to the agreement, Flamel will receive an upfront license fee of $3 million, as well as develop- ment-based milestones, and mid-single digit royalties upon eventual product sales.
For the first quarter 2011, Flamel reported total reve- nues of $6.8 million versus $8.1 million in the year- ago period. License and research revenues during the first quarter of 2011 were $3.2 million versus $3.4 million in the first quarter 2010. Product sales and services, relating to the supply of Coreg CR which the Company has continued to furnish to GSK while
11-04 :: April/May 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93